Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting

NCT ID: NCT00828555

Last Updated: 2012-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3988 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PURPOSE To develop, implement, and evaluate the effectiveness of a program designed to assist community Ob/Gyns in vaccinating adolescent and adult women against vaccine-preventable diseases.

SPECIFIC AIMS

1. Determine the feasibility of implementing a successful vaccination program for adolescent and adult women in Ob/Gyn offices by direct assessment of medical personnel \& office staff on their:

* Attitudes towards vaccination of women against preventable diseases
* Perceived barriers to implementing a program to vaccinate women in their offices
* Ideas on how to overcome barriers to successful program implementation
* Current vaccination practices and office-specific administrative processes
2. Design \& implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, \& pertussis
3. Determine the effectiveness of the vaccination program based on

* Pre- and post-program vaccination rates
* Program satisfaction amongst Ob/Gyn providers and office staff
* Willingness to continue and possibly extend the program to additional vaccines
4. Quantify the level of support and resources needed to develop and implement the vaccination program

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Vaccine Papillomavirus Infection Pertussis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HPV vaccine Tdap vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaccination Program

Design \& implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, \& pertussis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 4-5 community Ob/Gyn practices
Minimum Eligible Age

12 Years

Maximum Eligible Age

26 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centers for Disease Control and Prevention

FED

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Geeta Swamy, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Westside OBGYN

Burlington, North Carolina, United States

Site Status

DWHA

Durham, North Carolina, United States

Site Status

Atrium OBGYN

Raleigh, North Carolina, United States

Site Status

Blue Ridge OBGYN

Raleigh, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00011038

Identifier Type: -

Identifier Source: org_study_id